Skip to main content
. 2022 Feb 24;12:830816. doi: 10.3389/fonc.2022.830816

Figure 2.

Figure 2

Genomic features of ctDNA dynamically changed in colorectal cancer patients received anti-EGFR therapies. (A) The ctDNA genomic features for all specimens at baseline, remission, and progression in colorectal cancer patients who received cetuximab-targeted therapy. (B) The clonal and subclonal landscapes in mCRC patient at baseline, remission, and progression. Gain: segments with log ratio more than 3 times of standard deviation of all segment level were considered as “gain”.